Xu Diyong bought 1,250,000 shares of Q32 Bio Inc. at $8.00 for $10.0M on May 28, 2026

Buy
Form 4 code P. Open-market or private purchase of a non-derivative or derivative security.
Director
DIR
Filed Jun 1, 2026

Facts from the filing

Form 4 · Non-derivative, table I
Disclosed value
$10,000,000Shares × reported price
Shares traded
1,250,000Common Stock
Price per share
$8.00Reported price. Read footnotes for ranges.
% of reported position traded
55.48%This security and ownership context
Holdings after
3,502,987Indirect · See footnotes
Trade date
May 28, 2026Buy
Filed
Jun 1, 2026, 9:15 PM ET5-day reporting delay
Accession
0000947871-26-000594Code P · Transaction 388868
How reported position traded is calculated

Shares purchased ÷ (holdings after − shares purchased). Estimated position before: 2,252,987 shares.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
May 28, 2026Buy625,000$8.00$5,000,000Trade 388869
2 transaction rows in this filing. Joint filers share the same rows.

QTTB price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
QTTB · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago −55%1w ago −56%1d ago +1.7%
Returns since7d −5.9%30d +3.6%90d +18%180d1y

Footnotes in full

F1: These shares of the Issuer's common stock were purchased from the Issuer in a private placement. F2: These securities are held of record by OrbiMed Private Investments VII, LP ("OPI VII"). OrbiMed Capital GP VII LLC ("OrbiMed GP") is the general partner of OPI VII and OrbiMed Advisors LLC ("OrbiMed Advisors") is the managing member of OrbiMed GP. By virtue of such relationships, OrbiMed GP and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VII. F3: These securities are held of record by OrbiMed Genesis Master Fund, L.P. ("Genesis"). OrbiMed Genesis GP LLC ("Genesis GP") is the general partner of Genesis and OrbiMed Advisors is the managing member of Genesis GP. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by Genesis and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by Genesis. F4: Each of the Reporting Person, OrbiMed Advisors, OrbiMed GP, and Genesis GP disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such person or entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.